An Evaluation of the Long-term Safety of Magnesium Iron Hydroxycarbonate
Stopped early · Phase 2
Conditions studied: Chronic Kidney Failure
In brief
Fermagate is a phosphate binder that absorbs phosphate from food, reducing the amount that the body can absorb. The purpose of this study it to look at the safety of fermagate over longer periods of time.
Key facts
- Study ID
- NCT00358722
- Run by
- Ineos Healthcare Limited
- People needed
- 44
- Starts
- 2006-07-01
- Expected to finish
- 2008-06-01
- Last updated by the study team
- 2009-08-10
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Taken at least one dose of double-blind medication during study IH 001 and either completed study IH 001 or were withdrawn due to reasons other than an AE considered related to study treatment
- Male or female subjects on active haemodialysis, aged 18 years or over
- Willing to abstain from taking any phosphate binder or oral magnesium-, aluminium-, or iron-containing products and preparations, other than the study medication;
- Willing to avoid any intentional changes in diet such as fasting, dieting or overeating;
- Willing to maintain their usual type and dose of Vitamin D supplementation.
You may not qualify if…
- Participation in any other clinical trial using an investigational product or device within the previous 4 months;
- A significant history of alcohol, drug or solvent abuse in the opinion of the investigator;
- Any disease or condition, physical or psychological, which in the opinion of the investigator would compromise the safety of the subject or increase the likelihood of the subject being withdrawn;
- Clinically significant laboratory findings (for this subject population) in the opinion of the investigator.
- Any malignancy with the exception of basal cell carcinoma;
- A history of a motility disorder of the intestines, including, but not limited to, gastroparesis, ileus, pseudo-obstruction, megacolon, or mechanical obstruction;
- A significant illness in the 4 weeks before screening;
- Taking medication for seizures;
- A history of haemochromatosis;
- A history of serum ferritin concentration of ≥ 1000 ng/mL (excluding transient, treatment-induced ferritin elevation);
- A history of dysphagia or swallowing disorders;
- Female subjects who are lactating or pregnant. Women of childbearing potential (pre-menopausal and not surgically sterilised) unless they abstain from sexual intercourse or are using a reliable contraceptive method, that is, barrier methods, hormones or intrauterine device;
- Current haemoglobin concentration of < 10.00 g/dL;
- Allergy to the IMP or its constituents.
Where it is running
- 1614 West 42nd Street — Pine Bluff, Arkansas, United States
- US Renal Care — Stuttgart, Arkansas, United States
- Davita Dialysis Center — Charlotte, North Carolina, United States
- Southeast Renal Associates — Charlotte, North Carolina, United States
- Renal Unit, Birmingham Heartlands Hospital — Birmingham, United Kingdom
- St Lukes Hospital, Little Horton Lane — Bradford, United Kingdom
- Richard Bright Renal Unit, Southmead Hospital — Bristol, United Kingdom
- Addenbrookes Dialysis Centre, Addenbrookes Hospital — Cambridge, United Kingdom
- Renal Unit, Leicester General Hospital — Leicester, United Kingdom
- Dialysis Unit, Broad Green Hospital — Liverpool, United Kingdom
- Royal Liverpool University Hospital — Liverpool, United Kingdom
- General Medicine and Nephrology, Norfolk and Norwich University Hospital — Norwich, United Kingdom
- Nottingham Renal and Transplant Unit, Nottingham City Hospital — Nottingham, United Kingdom
- Sheffield Kidney Unit, Northern General Hospital — Sheffield, United Kingdom
- Dept. of Nephrology, Morriston Hospital — Swansea, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.